key: cord-0949285-azn577ca
authors: Yang, Jie; Liao, Xuelian; Yin, Wanhong; Wang, Bo; Yue, Jirong; Bai, Lang; Liu, Dan; Zhu, Ting; Huang, Zhixin; Kang, Yan
title: Elevated cardiac biomarkers may be effective prognostic predictors for patients with COVID-19: A multicenter, observational study
date: 2020-10-13
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.10.013
sha: dd6ecf3f3ceb0aad42a3e6dd2dc6326a239fb9de
doc_id: 949285
cord_uid: azn577ca

PURPOSE: The coronavirus disease 19 (COVID-19) has become a global health event. Cardiac biomarkers like creatine kinase isoenzyme (CK-MB), myoglobin, and high-sensitivity troponin T were usually elevated in early stages. This study aimed to investigate whether the elevated cardiac biomarkers could become effective prognostic predictors for COVID-19 patients. METHODS: The present study involved 357 COVID-19 patients. The potential predictors for two study outcomes (in-hospital death and recovery status) in 28 days were selected by LASSO regression analysis. Prognostic values of cardiac biomarkers selected were evaluated using the receiver operating characteristic curve (ROC) and the area under ROC (AUC). RESULTS: After 28-day follow-up, overall 357 patients were divided into death group (n = 25) and survival group (n = 332), or non-recovery group (n = 43) and recovery group (n = 314). The LASSO regression analysis showed elevated CK-MB and myoglobin were independent risk predictors for in-hospital death, and CK-MB and myoglobin were also independent risk predictors for non-recovery. The AUC of CK-MB and myoglobin for in-hospital death were 0.862 (95%CL: 0.804–0.920, p < 0.001) and 0.838 respectively (95%CL: 0.729–0.947, p < 0.001). The AUC of CK-MB and myoglobin for non-recovery were 0.839 (95%CL: 0.786–0.892, p < 0.001) and 0.841 (95%CL: 0.765–0.918, p < 0.001) respectively. We also found AUC of combined use of CK-MB and myoglobin for in-hospital death and non-recovery were 0.883 (95CL: 0.813–0.952, p < 0.001), and 0.873 (95%CL: 0.817–0.930, p < 0.001) respectively. CONCLUSIONS: In patients with COVID-19, elevated CK-MB and myoglobin on admission may be effective predictors for adverse outcomes, and combined use of CK-MB and myoglobin had a better performance for prediction.

The coronavirus disease 2019 due to SARS-CoV-2 infection broke out initially in Wuhan city, China, from December 2019 [1] . And COVID-19 has become a public health event of international concern and spread rapidly. Since now, there are no useful and specific medicines and treatment for COVID-19 [2] .

With increasing confirmed number of COVID-19 patients, many studies were conducted to reveal patient clinical characteristics. Abnormal change of characteristics and laboratory tests was more frequent in severe cases or deaths, such as complete blood count, plasma biochemical parameters, and inflammatory marks [3, 4] . As the related researches progressing, the researchers gradually discovered infection with SARS-CoV-2 may cause acute myocardial injury. Chaolin Huang and his colleagues reported that part of ICU patients with COVID-19 existed acute myocardial injury, which mainly showed an increase of high-sensitivity troponin I [5] . Some cardiac biomarkers including creatine kinase isoenzyme (CK-MB), myoglobin, and troponin I significantly elevated in long-term hospitalization than short-term hospitalization [6] . Dr. Chirag Bavishi reviewed related studies about COVID-19 and found overall prevalence of acute myocardial injury ranged from 5% to 38% in COVID-19 patients [7] . Therefore, myocardial injury and elevation of relevant cardiac biomarkers were common in patients with SARS-CoV-2 infection [8] .

Thus, how about the association between acute myocardial injury or abnormal change of cardiac biomarkers and patient prognosis. Some studies have investigated the relationship between acute myocardial injury and adverse prognosis. Dr. Alvaro Lorente-Ros and his (her) colleagues found Fisher's exact probability test. Normally distributed continuous variables were presented as mean ± standard deviation (SD), and compared by independent t-test. Non-normally distributed continuous variables were presented as medians and interquartile ranges, and compared using Mann-Whitney test. P<0.05 was considered statistically significant in comparing differences between survival and death groups, or recovery and non-recovery groups. Spearman correlation analysis was used to investigate the correlation between myoglobin and either CK-MB or high-sensitivity troponin T.

Potential risk predictors for in-hospital death or non-recovery were identified using least absolute shrinkage and selection operator (LASSO) regression analysis, and LASSO regression was a method of machine learning regression, which was used to choose independent risk factors affecting outcomes and applied to minimize the potential collinearity of the variables measured and overfitting of the variables. It is a logistic regression model penalizing the absolute size of the coefficients of a regression model based on the value of λ. With larger penalties, the estimates of weaker factors shrink toward zero, so that only the strongest predictors remain in the predictive model [11] . The ROC and AUC were built to assess the prognostic performance of predictors selected. All related statistics analyses were performed using R software 4.0.1.

In the present study, a total of 357 patients confirmed by COVID-19 and receiving laboratory test of cardiac biomarkers were enrolled between January 20 and March 15, 2020. According to patient survival status, 357 patients were divided into death group (n=25) and survival group (n=332). On the other hand, 43 patients did not recover in 28 days, and 314 patients recovered according to patient J o u r n a l P r e -p r o o f Journal Pre-proof recovery status after 28-day follow-up (figure 1). The median age of all patients was 56.0 (43.0, 68.0) years old, and 164 (45.9%) patients were older than 60 years old. 185 (51.8%) patients were male, and 154 (43.1%) patients were with coexisting disorders. The median time from symptoms onset to designated hospital was 9.0 (5.0, 15.0) days (table 1 and table 2 ).

The respiratory rates in death and non-recovery group were both significantly faster than survival and recovery group (24.0 (22.0, 30.0) versus 20.0 (19.0, 21.0), and 22.0 (19.0, 26.5) versus 20.0 (19.0, 21.0) ). Dyspnea in death and non-recovery group occurred more frequently than survival and recovery group (64% versus 28.9% and 58.1% versus 27.7%). Laboratory findings like aspartate aminotransferase, total bilirubin, creatinine, procalcitonin, CRP, D-dimer were also significantly higher in death and non-recovery group. However, other laboratory findings including platelet count, hemoglobin, and albumin significantly decreased in these two groups. Cardiac biomarkers including CK-MB, myoglobin, and high-sensitivity troponin T significantly elevated in death and non-recovery group in figure 2. Moreover, admission myoglobin was positively correlated with both CKMB and high-sensitivity troponin T (figure 3). Died patients or non-recovery patients used glucocorticoid and immunoglobulin more frequently than survival or recovery patients. The other clinical characteristics and their differences between the two groups were also presented in table 1 and table 2. 19 variables were included into the LASSO regression analysis to select potential predictors for in-hospital death or non-recovery in 28 days. The included variables were demographics (age≥60 and coexisting disorders), signs and symptoms (respiratory rate and dyspnea), laboratory findings (lymphocyte count, platelet count, hemoglobin, alanine aminotransferase, aspartate aminotransferase, J o u r n a l P r e -p r o o f Journal Pre-proof albumin, total bilirubin, creatinine, procalcitonin, CRP, prothrombin time, D-dimer, CK-MB, myoglobin and high-sensitivity troponin T. The LASSO regression results showed age≥60, dyspnea, respiratory rate, aspartate aminotransferase, albumin, total bilirubin, CRP, D-dimer, CK-MB and myoglobin were prognostic factors for in-hospital death when the binomial deviance was the smallest; and age≥60, dyspnea, hemoglobin, albumin, total bilirubin, CRP, D-dimer, CK-MB and myoglobin were prognostic factors for non-recovery when the binomial deviance was the smallest (figure 4).

Therefore, CK-MB and myoglobin were considered as potential predictors for adverse prognosis (in-hospital death or non-recovery) in 28 days. However, high-sensitivity troponin T was not a predictor for adverse prognosis according to LASSO regression analysis in this study.

The ROC and AUC of CK-MB and myoglobin for in-hospital death were 0.862 (95%CL: 0.804-0.920, p<0.001) and 0.838 (95%CL: 0.729-0.947, p<0.001), and the AUC of CK-MB and myoglobin for non-recovery were 0.839 (95%CL: 0.786-0.892, p<0.001) and 0.841 (95%CL: 0.765-0.918, p<0.001), respectively ( figure 5A, B) . Because previous studies as well as the present study showed higher CRP, D-dimer, total bilirubin, and high-sensitivity troponin T might be associated to COVID-19 patient adverse prognosis, we calculated the AUC of these variables and compared the prognostic performance among predictors selected [12] [13] [14] . As seen the figure 5C, D, the highest AUC for in-hospital death was were compared and analyzed. According to two outcomes in this study, patients were divided in survival group and death group, or recovery group and non-recovery group. 

A Novel Coronavirus from Patients with Pneumonia in China

Covid-19 -The Search for Effective Therapy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Clinical features of patients infected with 2019 novel coronavirus in

Risk Factors Associated With Long-Term Hospitalization in Patients With COVID-19: A Single-Centered, Retrospective Study

Acute myocardial injury in patients hospitalized with COVID-19 infection: A review

COVID-19 and the cardiovascular system

Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients

Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and Decision tree analysis

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

Prognostic value of C-reactive protein in patients with COVID-19

Biomarkers associated with COVID-19 disease progression

The diagnostic and predictive role of NLR, d-NLR and J o u r n a l P r e -p r o o f Journal Pre-proof PLR in COVID-19 patients

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of refractory COVID-19 pneumonia in

Covid-19: risk factors for severe disease and death

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China

Approach to Acute Cardiovascular Complications in COVID-19 Infection, Circ Heart Fail

Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Apparent elevation of serum CK-MB not due to acute myocardial infarction

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review

Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction

Biochemical tissue-specific injury markers of the heart and brain in postpartum cord blood

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure

years, median (Q1, Q3) , breaths per min

High-sensitivity troponin T, ng/mL, median (Q1, Q3)

%) , breaths per min

High-sensitivity troponin T, ng/mL, median (Q1, Q3)